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Summary for use on social media: 
During device implantation the RADPAD® cap decreased the skin front head exposure but had 
no impact on brain dose distribution as the exposure comes from upwards scattered radiation. 





Objectives. Our study investigates the RADPAD® No Brainer® efficiency in reducing brain 
exposure to scattered radiation. 
Background. Cranial radioprotective caps such as the RADPAD® No Brainer® are being 
marketed as devices that significantly reduce operator’s brain exposure to scattered radiation. 5 
The efficiency of the RADPAD® No Brainer® in reducing brain exposure in clinical practice 
remains, however, unknown to date. 
Methods. Five electrophysiologists performing device implantations over a two-month period 
wore the RADPAD® cap with two strips of 11 thermo luminescence dosimeters pellets covering 
the front head above and under the shielded cap. Phantom measurements and Monte Carlo 10 
simulations were performed to further investigate brain dose distribution.  
Results. Our study showed that the right half of the operators' front head was the most exposed 
region during left subpectoral device implantation; the RADPAD® cap attenuated the skin front 
head exposure, but provided no protection to the brain. The exposure of the anterior part of the 
brain was decreased by a factor of 4.5 compared to the front head skin value thanks to the skull. 15 
The RADPAD® cap worn as a protruding horizontal plane, however, reduced brain exposure 
by a factor of 1.7 [1.3 ; 1.9]. 
Conclusion. During device implantation, the RADPAD® No Brainer® decreased the skin front 
head exposure but had no impact on brain dose distribution. The RADPAD® No Brainer® worn 
as a horizontal plane worn around the neck reduces brain exposure and confirms that the 20 
exposure comes from upwards scattered radiation. 
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Clinical measurements, phantom measurements and Monte Carlo simulations were performed 
to investigate the RADPAD® No Brainer® efficiency in reducing brain exposure to scattered 
radiation. The RADPAD® No Brainer® worn as a cap decreased the skin front head exposure 





CHUV: Lausanne University Hospital 
CRT: Cardiac Resynchronization Therapy 
Hp(0.07): Skin Personal Dose Equivalent  
Hp(10): Personal Deep Dose Equivalent  5 
ICD: Implantable Cardioverter Defibrillator 
IRA: Institute of Radiation Physics 
PM: Pacemaker  
TLD: Thermo Luminescence Dosimeter 





Several cases of malignant tumors affecting the brain, head or neck have been published over 
the last decade, with predominantly left-sided lesions for interventionalists practicing with the 
X-Ray tube on their left side (1). Although a direct link between interventionalists exposure 5 
and brain tumor has not been strictly established yet, a recent review has raised concerns about 
a potential association (1). Cranial radioprotective caps are being marketed as devices that 
significantly decrease brain exposure during fluoroscopically-guided interventions (2). The 
RADPAD® No Brainer® is a lead-equivalent surgical cap that supposedly reduces exposure to 
scattered radiation from 50% to 95% (3). However, data showing any benefit of the efficiency 10 
of the RADPAD® No Brainer® on brain exposure are missing. The efficiency of the RADPAD® 
No Brainer® in reducing brain exposure in real-life conditions such as during pacemaker (PM) 
and implantable cardioverter defibrillator (ICD) interventions remains unknown to date. Our 
study is aimed at measuring head and brain electrophysiologists exposure reduction provided 




2.1.1. Surgical cap 
The cap used in this study was the RADPAD® No Brainer® surgical cap with a lead equivalence 20 
of 0,25 mm (at 90 kVp), manufactured by Worldwide Innovation & Technologies, inc (Kansas, 





This study was conducted using Thermo Luminescence Dosimeters (TLD, LiF: MCP-N, Mg, 
Cu, P) pellets provided by the dosimetry service of the Institute of Radiation Physics (IRA) of 
the Lausanne University Hospital (CHUV). All raw data are provided as absorbed dose in water 
(Gy). A correction factor was applied to evaluate the skin personal dose equivalent Hp(0.07) for 5 
an energy of 50 keV to compensate for the energy response of the detector. No correction factor 
was applied to evaluate brain exposure. In this article TLD measurement data are given with an 
uncertainty of 4% (k=1). In addition, an electronic personal dosimeter (DMC 3000, Mirion 
Technologies, France) was used to estimate the effective dose delivered to the medical staff 
during measurements under controlled conditions (with phantoms). The results are provided as 10 
personal deep dose equivalent Hp(10). DMC 3000 measurement data are given with an 
uncertainty of 10% according to the supplier. 
 
2.1.3. Phantoms 
Measurements under controlled conditions were performed using an Alderson RANDO 15 
anthropomorphic phantom (model 200, RSD, USA) to represent the implanting physicians 
standing next to the X-Ray tube. A heart/thorax phantom (model 800, RSD, USA) was used to 
simulate the patient generating the scattered radiation field on the intervention table. 
 
2.1.4. Monte Carlo simulations 20 
Monte Carlo simulations were performed with the Geant4 toolkit (4) to compute the absorbed 
dose in the brain received by a physician staying beside a patient lying on a table and irradiated 
from the bottom by the scattered radiation field (figure 1S - supplemental data) .  
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In this model the patient is represented by a water cylinder phantom. The physician is 
represented by the ICRP Male voxel phantom (5). “Without skull” simulations were performed 
replacing skull voxels by air instead of bone tissue in the ICRP voxel phantom. The center of 
the head of the ICRP phantom was set at a distance of 97 cm and an angle of 33 degrees from 
the center axis of the cylinder patient. The 33-degree angle represents the angle between the 5 
vertical direction of the X-Ray tube and the direction passing through the patient’s scattering 
center and the ICRP phantom’s head.  
The RADPAD® is represented by three adjacent lead foils, with a thickness of 250 µm and an 
height of 10 cm surrounding the upper part of the front head. These RADPAD® foils are set 
along the box-limit of the voxel head phantom.  10 
The X-Ray tube is placed below the couch irradiating from the bottom (vertical direction) 
directly on the patient water cylinder with a square field of 20 x 20 cm; the physician is 
exposed to scattered radiation coming upwards from the patient. The primary X-Ray spectrum 
considered in the simulation was generated with an online tool for a peak voltage of 75 kVp 
(6), with 0.3 mm Cu and 1 mm Al filtration representative of the conditions used in clinical 15 
routine. A statistics of 6.109 primary X-Rays were generated for each simulation. 
 
2.1.5. Imaging system 
The imaging system used is an Axiom Artis dFCMN (Siemens Healthcare, Germany). Clinical 
measurements were performed in fluoroscopy mode with the following settings:  a mean tube 20 
tension between 70 and 80 kV (table 1), a current intensity of 155 mA, a square field of 20 x 
20 cm and 3 frames per second (fps). Measurements under controlled conditions were 
performed in the cine mode with the following settings:  tube tension 61.5 kV, current intensity 
~ 600 mA, square field 20 x 20 cm, 30 fps. The “cine mode” was used to reach a sufficient 
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cumulative dose level in a reasonable time to minimize dosimeters measurements uncertainties. 
These data are still transferable to the clinical setting as the cine mode appears to have a limited 
impact on beam quality in our specific case. 
 
2.1.6. Statistical analysis 5 
A linear mixed-model with random effects was applied to estimate the mean differences in 
personal dose equivalent between cap sides (under vs above the cap) at each position around 
the head. In this model, the electrophysiologists were treated as a random factor, while cap side 
and position were considered as the fixed predictive factors. This method takes into account the 
lack of independence of measures repeated within the electrophysiologists. Our interest was in 10 
testing the statistical interaction between cap side and position. Its existence would show that 
the differences between measures under and above the cap vary according to the position around 
the head. A Wald chi-squared test was applied to test whether the multiple interaction terms in 
the model were jointly significant. After statistically significant Wald test, model predicted 
mean cap side differences at each position were estimated together with Bonferroni-corrected 15 
95% confidence intervals to account for multiple testing. The analyses were performed with the 
statistical package Stata/IC, version 16.0 (StataCorp LLC, College Station, TX, USA). Data are 
presented as mean values and standard deviation. The attenuation factor provided by the skull 
(table 1S – supplemental data) was calculated as the ratio of the skin absorbed dose upon the 




2.2. Clinical measurements 
Five operators from the Arrhythmia Unit of the service of Cardiology in CHUV participated in 
this study over a two-month period in order to cumulate enough dose to reach the detection 
limit of the TLDs to become significant for comparisons. Operators’ exposure came from 
scattered radiations delivered by the patients with the X-Ray tube standing vertically below the 5 
table during most of the procedures. Each physician was asked to wear a RADPAD® cap on 
which two strips of 11 TLD pellets were equally interspaced every 2 cm on the anterior half of 
the pad covering the front head above and under the shielded material (figure 1A). A shield 
hanging below the table and placed between the operator and the tube was systematically used 
during implantations. The measurements were performed without any distinction between the 10 
different procedures routinely performed in the unit: permanent PM, ICD or cardiac 
resynchronization therapy (CRT). This study received formal exemption from the CER-VD 
(Switzerland) ethics committee, as the project does not collect data from the participants. Table 
1 (and table 2S - supplemental data) details for each implanting physician the number of 
procedures as well as the total fluoroscopy time, the mean voltage and total dose area product, 15 
which is used to assess the patient’s radiation risk for an interventional procedure. For technical 
reasons, the mean voltage for implanting physician number 5 was not available. 
 
2.3. Measurements under controlled conditions 
The RANDO phantom (figure 1B) representing the implanting physician was equipped with 33 20 
TLDs evenly placed intracranially, a strip of 11 TLD pellets equally distributed every 2 cm on 
the phantom front head (red arrow) and an operational dosimeter positioned on the phantom 
chest (green arrow). Two sets of measurements were performed. The first set was completed 
bareheaded, i.e. without the RADPAD® cap, while the second one was performed with a 
RADPAD® cap protecting both intracranial and front head TLDs. As a second step (figure 1C), 25 
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the RANDO phantom with the 33 intracranial TLDs and the operational chest dosimeter was 
equipped with the RADPAD® protection worn as a protruding horizontal plane. The objective 
of the specific set-up with the protective gear worn as a protruding horizontal plane below 
the chin is to demonstrate that the dose to the brain is due to upwards scattered radiation, 
but not to propose a new solution to be used in clinical routine. 5 
 
3. Results 
3.1. Clinical efficiency of the RADPAD® No Brainer® surgical cap 
Table 2 and figure 2A report the skin personal dose equivalent Hp(0.07) along the front head of 
the five operators above (blue) and under (red) the RADPAD® cap. The mixed-model produced 10 
a statistically significant interaction between cap sides and position around the head (Wald test: 
p<0.001), indicating that the difference in cumulated dose between cap sides changes according 
to the position around the head. Model based estimations show under the cap a fairly constant 
mean cumulated dose from the left to the right temple, while the mean dose increased from the 
left to the right temple above the cap, being clearly above the under-cap values from position 15 
F5 to the right temple (Table 2 and figure 2A). This asymmetric distribution stemmed from the 
position of the operators standing on the left side of the patients’ chest with their right temple 
directed towards the X-Ray tube. Figure 2B shows that the mean difference between cap sides 
is almost inexistent from the left temple until position F3, starts increasing from position F4 
with a maximum on the front head, and remains high from F7 to the right temple (Table 2, table 20 
2S – supplemental data and figure 2B). All cap side differences between F5 and the right temple 
bear a statistically significant difference from zero (Table 2, table 2S – supplemental data and 
figure 2B). The maximum two-month cumulated skin personal dose equivalent Hp(0.07) 
reached less than 250 Sv (figure 2A, blue line), resulting in a maximum estimated dose of 2 
mSv/year to the operator’s skin when the head was not protected by the RADPAD® cap.  25 
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3.2. Efficiency of the RADPAD® No Brainer® surgical cap evaluated with phantoms 
During measurements under controlled conditions, an attenuation factors of 2.3 for skin 
exposure provided by the RADPAD® cap along the front head was calculated. These 
measurements (figure 3A, red box) show that the attenuation factors for brain exposure with 
the RADPAD® cap is close to the unit (1.1 [1.0 ; 1.1], median and interquartile values), hence 5 
providing no protection to the brain. There was no correlation between front head skin dose and 
brain dose as the dose to the brain remained the same regardless of the cumulated personal dose 
equivalent at the front head skin. Figure 3B reports the absorbed dose distribution into the brain 
from the vertex (slice 1) to the base (slice 3) of the skull. Note the anteroposterior absorbed 
dose gradient as shown by higher values in front head TLDs (e.g. TLDs 21) and lower ones for 10 
occipital ones (e.g. TLDs 3), which is coherent with the operator’s position relative to the X-
Ray tube. Similarly, a caudocranial absorbed dose gradient is observed as shown by higher 
values for basal TLDs and lower ones for vertex TLDs (e.g. TLD 8 and 12). This finding 
matches with the position of the operator’s head standing above the patient. The phantom was 
then equipped with the RADPAD® No Brainer® protection worn as a protruding horizontal 15 
plane. Interestingly, measurements under controlled conditions (figure 3A, green box) show a 
1.7 [1.3 ; 1.9] (median and interquartile values) attenuation factor for brain exposure, which is 
significantly higher than the value for the RADPAD® worn as a cap. 
The ratio for the chest personal dose equivalent Hp(10) over the skin personal dose equivalent 
Hp(0.07) was 1.1 (table 1S – supplemental data), meaning that the chest personal dose 20 
equivalent is representative of the front head value measured without any RADPAD® 
protection. An attenuation factor of 4.5 for the skin absorbed dose at the median front head over 
the anterior brain absorbed dose (TLD 21) was reported (table 1S – supplemental data). This 
attenuation factor of 4.5 between the skin front head equivalent dose and the brain equivalent 
dose just below the bone suggests that the shielding effect is significant and that the skull is 25 
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more efficient than the RADPAD® in protecting the brain for direct exposure (an additional 
protective material should be considered for the exposure from upwards scattered radiation). 
 
3.3. Evaluation of the efficiency of the RADPAD® No Brainer® surgical cap using 
Monte Carlo simulations 5 
The absorbed dose distribution for a slice of brain (colored map) and the mean absorbed dose 
in the brain under free conditions are reported in figure 2S – supplemental data: panel A, 
without both the skull and the RADPAD® cap; panel B, with the skull but without the 
RADPAD® cap; panel C, with both the skull and the RADPAD® cap. As expected, the brain 
front head exposure (10-6 to 10-7 pGy/X-Ray) was greater than that of the brain back head (10-10 
7 to 10-9 pGy/X-Ray) with and without the skull and RADPAD® cap. Note the lower exposition 
values of the brain provided by the skull (panels B [7,23.10-8 pGy/X-Ray] and C [7,10.10-8 
pGy/X-Ray] vs A [1,35.10-7 pGy/X-Ray]) and the lack of protective effect of the RADPAD® 
as shown by similar exposure distribution between panels B (without) and C (with the 
RADPAD® cap). Taken together, these simulations suggest that an efficient shielding against 15 
radiation is provided to the brain by the skull, but not by the RADPAD® worn as a cap. 
 
4. Discussion 
This prospective study encompasses several observations and new findings for 
electrophysiologists performing device implantations summarized as follow: the right half of 20 
the front head’s physician is the most exposed region for device implantation performed at the 
patients’ left subpectoral region; the RADPAD® cap attenuates the skin front head exposure, 
but provides no protection to the brain; the exposure of the anterior part of the brain is decreased 
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by a factor of 4.5 compared to the front head skin value thanks to the skull; the RADPAD® cap 
worn as a protruding horizontal plane decreases brain exposure by a factor of 1.7. 
 
4.1. Clinical efficiency of the RADPAD® No Brainer® surgical cap 
Several studies on the efficiency of radiation protection surgical caps were published over the 5 
past few years (7). The first studied lead cap (0.5 mm lead equivalent) was quite heavy (1140 
g) and wrapped the head and neck, with an opening for the eyes, nose and mouth (8,9). Both 
studies reported a significant attenuation of the head exposure compared to the control 
conditions mostly for interventionalists performing coronary angiography from the patients’ 
right groin. More recent studies evaluated the efficiency of two models of lightweight lead-free 10 
caps worn as a front head band: XPF® caps (1,10,11) and RADPAD® No Brainer® surgical caps 
(2,12,13). Importantly, the lead equivalence of the studied caps were different (0.06 mm (2), 
0.125 mm (12), 0.25 mm (13), 0.3 mm (11), 0.5 mm (1,10,11)). In four publications, the 
efficiency of the cap was evaluated by placing dosimeters at a single position on the left 
temporal front head (2,10,11,12). Two studies assessed the efficiency of the cap with a limited 15 
number of dosimeters placed at two (13) or three (1) positions on the front head. Although the 
number of screened positions was limited, the exposure of the front head portion turned toward 
the X-Ray tube was the highest (1,13). As far as we know, our study is the first that monitored 
the skin personal dose equivalent Hp(0.07) of the full front head from the right to the left temple, 
placing dosimeters at 11 positions. Here, in contrast to studies where interventionalists 20 
performed neurovascular or coronary procedures (1,2,10,11,12,13) from the right femoral side 
of the patients, the implanting electrophysiologists stood at the left subpectoral region very 
close from the X-Ray tube. Our results showed that the right side of the head has a significantly 
higher exposure (factor of 2.4, figure 2A) than the left one, which is in agreement with former 
conclusions (1,13).  25 
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In five publications, the efficiency of the protection devices was evaluated by placing 
dosimeters above and under the cap (1,2,10,11,12). The dose measured under the cap was 
significantly lower than that measured above on the most exposed side. Our results are in 
agreement with these findings as the skin personal dose equivalent Hp(0.07) measured under 
the RADPAD® cap was significantly lower than that measured above at seven locations on the 5 
most exposed side (table 2). Sans Merce et al. (13) recently reported the lack of significant 
impact of the cap on the dose measured on the head, even on the most exposed side, which 
contradicts our observations and those from the literature (1,2,10,11,12). Differences in 
methodology may explain these contradictory results: first, their measurements were 
sequentially performed with the dosimeter covered by the RADPAD® cap only during the 10 
second period, and, second, with a biplane imaging system. In summary, the RADPAD® cap 
reduces the skin exposure of the most exposed side of the front head. Note that the maximum 
dose to the operator’s skin upon the RADPAD® cap was estimated to be 2 mSv/year, which is 
far below the skin limit of 500 mSv/year fixed by the Swiss Radiological Protection Ordinance 
(14, 15). 15 
 
4.2. Efficiency of the RADPAD® No Brainer® surgical cap evaluated with phantoms 
Kirkwood et al. (2) studied the efficiency of the RADPAD® cap (0.06 mm lead equivalent) 
using an anthropomorphic head phantom. First, the consistency between the phantom study and 
the clinical data was assessed by placing a dosimeter on the phantom head surface at the left 20 
temporal position, with and without the cap. These results were compared to the data measured 
under and above the cap at the left temporal location of the surgeon’s head. A similar attenuation 
in the range of 60 to 70% was found in both studies. Using the same measurement method but 
with TLDs all along the front head surface, our phantom measurements showed a median 
attenuation factor of 2.3 for skin exposure, consistent with our clinical data showing a 2.2 25 
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median attenuation factor along the front head as provided by the cap. Second, these authors 
(2) reported that the RADPAD® cap provided no significant dose decline at the midbrain level 
and minimal dose decline at the upper brain level. Our findings are in agreement with their 
results as the attenuation factor for brain exposure provided by the RADPAD® cap was 
negligible (1.1), meaning that the brain exposure was the same whether the cap was worn or 5 
not. In addition, the attenuation factor for skin exposure (2.3) was twice that for brain exposure 
(1.1). Our study supports Kirkwood et al.’s (2) conclusion by showing that the attenuation 
measured on the surface of the head does not reflect the efficiency of the cap in reducing brain 
exposure. Third, Kirkwood et al. (2) claimed that brain exposure originates from the lower head 
and neck, which are regions not protected by the cap. As far as we know, our study is the first 10 
where phantom measurements assessed the dose distribution inside the brain (figure 3B). Our 
results revealed a caudocranial absorbed dose gradient that support previous findings (2). In 
addition, our phantom measurements were performed with the RADPAD® worn as a protruding 
horizontal plane to protect lower head and neck region (figure 1C). A median attenuation factor 
for brain exposure of 1.7 was found that was significantly higher than that measured when worn 15 
as a cap (figure 3A). In summary these findings demonstrate that the dose to the brain 
results from upwards scattered radiation delivered by the patient that do not pass through 
the cap, while the RADPAD® worn as a protruding horizontal plane significantly reduced 
brain exposure. 
 20 
4.3. Evaluation of the efficiency of the RADPAD® No Brainer® surgical cap using 
Monte Carlo simulations 
Our clinical and phantom measurements found that the RADPAD® worn as a cap reduces skin 
but not brain exposure. Marsh RM et al. (16) recently estimated that approximately 40% of the 
scattered radiations are absorbed by the skull and never reach the brain. We therefore 25 
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hypothesized that the protective effect of the skull overcomes the RADPAD® cap efficiency in 
reducing brain exposure. In our phantom measurements, a 4.5 attenuation factor was provided 
by the skull for two nearby anterior positions above and under the cranium. Monte Carlo 
simulations were performed to provide a direct comparison between a normal head and a fictive 
situation without the skull (figure 2S – supplemental data). The data indicate that the skull 5 
provides such a protection that the RADPAD® worn as a cap yields a marginal benefit. In 
summary, the skull appears as an efficient shielding for the brain but the RADPAD® worn as a 
cap provides marginal protection. 
 
4.4. Limitations 10 
The following limitations can be acknowledged.  
First, clinical measurements were performed without any distinction between the different 
procedures routinely performed in the unit. The aim was to get enough dose on the dosimeters 
at the end of the measurement period (compared to the detection limit of the dosimeters). The 
detection limit of the dosimeters couldn’t be reached by measuring the dose for each procedure 15 
type separately. Second, the impact of operator’s height has not been tested. The scope of this 
paper is aimed at investigating the efficiency of the protective cap under representative routine 
workload, where the potential impact of each operator’s morphological parameter has not been 
considered. Third, measurements under controlled conditions have only been performed with 
the tube in a vertical position, while the clinical measurements included several tube angulations 20 
left to the discretion of the operators. These experimental measurements were also performed 
in cine mode assuming that these data are still transferable to the clinical setting as they have 
minor impact on beam quality. The tube voltage (kVp) in cine mode, however, are 10% lower 
than the voltage used in fluoroscopy mode. This difference in mean beam energy (~ 8 keV) in 
the primary beam is considered negligible on the characteristics of the scattered radiation field. 25 
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Fourth, in our Monte Carlo simulations, the RADPAD® is represented by three adjacent 
lead foils, whereas the RADPAD® No Brainer® is actually composed of an alloy of tin and 
bismuth. Precautions have be taken with regards to the thickness of lead foils (250 µm), 
so that it corresponds to the lead-equivalent thickness of the protective material of the 
RADPAD® No Brainer® for the tube tension used by the staff during the procedures (Pb-5 
eq thickness of 0.25mm at 90kVp). Fifth, similar results were surprisingly found for 0.06 
mm and 0.25 mm lead equivalent RADPAD® caps, which is suggestive of a contribution 
from internal scattered radiation. Future research beyond the scope of the present 
manuscript should evaluate the contribution of the internal scattering as a function of the 
type of procedures (kVp, tube position and angle) and the type of protective gears used 10 
during procedures (both collective and personal). Finally, the objective of the specific set-
up with the protective gear worn as a protruding horizontal plane below the chin was to 
demonstrate that the dose to the brain is due to upwards scattered radiation, but not to propose 
a new solution to be used in clinical routine. Our results suggest that the lack of efficiency of 
the RADPAD® worn as a cap does not come from the RADPAD® gear itself but from its 15 
position on the front head. Future research beyond the scope of the present manuscript should 
compare the efficiency of the RADPAD® worn as a protruding horizontal plane to existing 
radiation protection options (Zero Gravity, RADPAD® drape, etc.) placed directly between 
operators and the scattered X-Ray source. 
 20 
4.5. Conclusion 
This study shows that the right half of the front head’s physician is the most exposed region for 
device implantation performed at the patients’ left subpectoral region. The RADPAD® No 
Brainer® worn as a cap did not provide protection to the brain because of upward scattered 
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radiation coming from the patient. The same gear worn as a protruding horizontal plane below 
the chin reduced brain exposure by a factor of 1.7.  
19 
 
Clinical Perspectives  
The right half of the front head’s physician is the most exposed region for device implantation 
performed at the patients’ left subpectoral region. The RADPAD® cap attenuates the skin front 
head exposure, but provides no protection to the brain. The exposure of the anterior part of the 
brain is decreased by a factor of 4.5 compared to the front head skin value thanks to the skull. 5 
The RADPAD® cap worn as a protruding horizontal plane does reduce brain exposure by a 
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Figure titles and legends 
Figure 1. Material. (A) RADPAD® cap equipped with TLDs distributed along the phantom 
front head. (B) Upper left: TLDs placed inside the phantom brain. Upper right: TLDs along the 
front head (red arrow) with operational dosimeter on the chest (green arrow). X-Ray exposure 
of the phantom without (lower left) and with (lower right) the RADPAD® cap. (C) RADPAD® 
cap worn as a protruding horizontal plane. X-Ray exposure of the phantom with TLDs 
placed in the brain (red arrow) and operational dosimeter placed on the chest (green arrow). 
 
Figure 2. Evaluation of the efficiency of the RADPAD® No Brainer® surgical cap using clinical 
measurements. (A) Model estimated mean two-month cumulated personal dose equivalent 
Hp(0.07) along the front head above and under the RADPAD
® cap for each position, with 95% 
confidence intervals. (B) Model estimated mean differences with Bonferroni-corrected 95% 
confidence intervals.  
 
Figure 3. Evaluation of the efficiency of the RADPAD® No Brainer® surgical cap using 
phantoms measurements. (A) Red: Attenuation factor for brain exposure with the RADPAD® 
No Brainer® protection worn as a front head cap. Green: Attenuation factor for brain exposure 
with the RADPAD® No Brainer® protection worn as a protruding horizontal plane. (B) 





Table 1. Procedures and X-Ray data per implanting physician 
 Number of 
procedures 
Cumulative  




Total dose area 
product 
(cGycm2) 
Op 1 15 60.25 70.23 8089.00 
Op 2 13 87.03 72.39 8940.90 
Op 3 15 171.45 71.82 22328.10 
Op 4 5 146.19 78.30 28558.50 








F2 F3 F4 F5 
F6 
Front head 





above the cap 
[µSv] 
















16.7 16.7 16.8 17.1 17.6 18.1 18.8 19.6 20.5 21.5 22.6 
Mean 
cumulated dose 
under the cap 
[µSv] 

















12.3 12.4 12.7 13.3 14.0 14.8 15.8 16.9 18.0 19.2 20.5 
Bonferroni 
p-value 
1.000 1.000 1.000 0.573 0.006 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
P-values for the estimated mean differences are Bonferroni-corrected. 
Scattered radiation reaches the operator’s head from
below, preventing any efficiency of the RADPAD® worn
















Figure 1S - supplemental data
A
B






Supplemental figures titles and legends 
 
Figure 1S. Monte Carlo simulations. (A) Visualization of the geometrical model used in the 
GEANT4  Monte Carlo simulations for the shielding capability of the RADPAD. (B) X-Ray 
spectrum considered in the GEANT4 Monte Carlo simulations. 
 
Figure 2S. Evaluation of the efficiency of the RADPAD® No Brainer® surgical cap using 
Monte Carlo simulations. (A) Absorbed dose distribution in the brain without both the skull 
and the RADPAD® cap, (B) with the skull but without the RADPAD® cap, (C) with both the 






Table 1S – Supplemental data. Correction factor from chest to skin dose and attenuation factor 
provided by the skull 
 Dose 
Chest personal dose equivalent Hp(10) [μSv] 872 
Skin personal dose equivalent Hp(0.07) [μSv] 799 
Correction factor 1.1 
Skin absorbed dose [μGy] 747 
Brain absorbed dose – position 21 [µGy] 167 
Attenuation factor provided by the skull  4.5 
3 
 
Table 2S - supplemental data. Details of the implanted devices with respective fluoroscopy time and dose area product 
  
Single and double chamber 
pacemakers 
Single and double chamber 
implantable cardioverter 
defibrillator 
Cardiac resynchronization therapy 

















area product  
(cGycm2) 
Op 1 10 4.78 661.71 5 3.67 431.58 0 - - 
Op 2 10 6.51 716.63 2 5.11 875.80 1 11.75 742.70 
Op 3 9 1.92 368.47 0 - - 6 25.70 3168.65 
Op 4 1 1.80 223.90 0 - - 4 36.10 7083.65 
Mean  4.40 577.45  4.08 558.50  28.21 4371.75 
Standard 
deviation 




Table 3S – Supplemental data. Model estimated mean difference of two-month cumulated personal dose equivalent Hp(0.07) above and under 




F2 F3 F4 F5 
F6 
Front head 





-6.5 - 3.2 - 11.2 - 38.9 - 69.6 - 118.5 - 88.2 - 91.8 - 94.1 - 107.9 - 103.0 
Bonferroni 
95% CI 
- 63.3, 50,3 - 59.9, 53.6 - 68.0, 45.5 - 95.6, 17.9 - 126.3, - 12.8 - 175.3, - 61.8 - 145.0, - 31.5 - 148.6, - 35.1 - 150.9, - 37.4 - 164.7, - 51.2 - 159.7, - 46.2 
The 95% confidence intervals are Bonferroni-corrected. 
 
